







































Before radiation

1 year after radiation



Pain control

- Short-term relief
 - Topical anesthetic mouthrinse
 such as "Magic moutwash" 2% viscous lidocaine
 mixed with equal volumes of diphenhydramine and a soothing
 covering agent in equal volumes for rinsing
 - Saline mouth rinses
 - o Ice chips
- Coating agents
 - o Sucralfate: commonly used , no significant decrease in the pain control
 - Topical agents, most patients with severe mucositis require systemic analgesics, often including opioids, for satisfactory pain relief
- Use of narcotic drug:
- Transdermal fentanyl
- Morphine mouth rinse
- Doxepin mouth rinse

BANGKOK HOSPITAL

Control of Oral Bleeding

- Commonly available materials in the dental clinic to assist in stopping of bleeding episode include pressure pack, ice application, vasoconstrictors and suturing
- The stent was fabricated with a thermoplastic silicone rubber under vacuum
- The hemostatic agent used was one 500 mg capsule of tranxemic acid that was crushed and applied as a paste every 6 hourly





Therapeutic Interventions

- 1. Growth factors and cytokines
- 2. Anti-inflammatory agents
- Antimicrobials, coating agents, anesthetics, and analgesics
- 4. Laser and other light therapy
- 5. Natural and miscellaneous agents

BANGKOK

GROWTH FACTORS

- Rationale: various growth factors that enhance epithelial cell proliferation differentiation, and migration
- IV rhuman KGF-1, Palifermin reduced incidence of grades 3 and 4 oral mucositis in patients with hematologic malignancies receiving high-dose chemotherapy and total body irradiation before autologous hematopoietic cell transplantation
- One recent study found no significant difference in survival between subjects with colorectal cancer receiving Palifermin or placebo at a median follow-up duration of 14.5 months
- Further ongoing studies to confirm the safety of epithelial growth factors in the solid tumor setting, including patients receiving radiation therapy for H&N cancer

...,



BANGKOK

CYTOKINES

- Preclinical models demonstrate that IL-1, IL-2, EGF, IL-11, and TGF-β have direct effect on intestinal or oral mucosa.
- IL-1 increases thymidine labeling, and protects oral and intestinal mucosa
- when given to mice before radiation IL-11 can decrease mucositis, when given to hamster models

.

BANGKOK

Anti-inflammatory agents Benzydamine hydrochloride is a non-steroidal anti-

- inflammatory drug
- Inhibit the production of pro-inflammatory cytokines such as tumor necrosis factor-α and interleukin-1β
- Recommendation
 - o **PREVENT oral mucositis** in patients with H&N cancer who were receiving moderate-dose RT up to 50 grays in patients not receiving concomitant chemotherapy

BANGKOK

Anti-inflammatory agents

- RK-0202
 - o Antioxidant, N-acetylcysteine
 - o Topical application in the oral cavity
 - o A placebo-controlled phase II trial in patients with H&N cancer significantly reduced the incidence of severe oral mucositis up to doses of 50-Gy radiation therapy
- β- carotene
 - o a scavenger of singlet oxygen
 - o supplemental dietary β-carotene lead to a mild decrease in the severity of chemotherapy and radiotherapy-induced oral mucositis

BANGKOK

Anti-inflammatory agents

- Saforis Oral suspension of L-glutamine
- o Enhances the uptake of this amino acid into epithelial cells
 - Reducing the production of pro-inflammatory cytokines and cytokine-related apoptosis
 - o Promote healing
 - o Reduce the incidence of chemotherapy-induced oral mucositis
 - o MASCC/ISOO guidelines recommend that systemically administered glutamine NOT be used for the prevention of GI mucositis because of lack of efficacy
- Amifostine
 - o Recommended for the **prevention** of esophagitis in patients receiving chemo-radiation for non small-cell lung cancer



BANGKOK

Laser therapy





• Only low-level laser treatment was found to be effective in reducing the severity of mucositis





BANGKOK

Low -Level Laser Therapy

- Reducing the symptoms related to oral mucositis
- · LLLT may reduce levels of ROS and/or proinflammatory cytokines that contribute to the pathogenesis of mucositis
- Guidelines suggest the use of LLLT for reducing the severity of chemotherapy and radiotherapyinduced oral mucositis





MASCC/ISOO for Low -Level Laser Therapy

- Recommendation in favor of LLLT for the prevention of oral mucositis in patients receiving high-dose chemotherapy for HSCT w or w/o total body irradiation
- Suggestion for LLLT in the prevention of oral mucositis in patients receiving H&NRT w/o concomitant chemotherapy
- (based on 24 studies)



Pilocarpine Pilocarpine Pilocarpine is a cholinergic agonist that stimulates salivary secretion The present systematic review supported 2 new suggestions against the use of systemic pilocarpine specifically for the prevention of oral mucositis: during H&NRT patients receiving high-dose chemotherapy, with or without total body irradiation, before HSCT Pilocarpine can be beneficial to increase salivary flow, particularly in patients treated with H&NRT who are experiencing













